Get the Stockscreener App
7.32
4.94%
-0.38
Corvus Pharmaceuticals Inc stock is traded at $7.32, with a volume of 901.05K.
It is down -4.94% in the last 24 hours and down -9.07% over the past month.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
See More
Previous Close:
$7.70
Open:
$7.78
24h Volume:
901.05K
Relative Volume:
0.75
Market Cap:
$546.67M
Revenue:
-
Net Income/Loss:
$-27.03M
P/E Ratio:
-13.07
EPS:
-0.56
Net Cash Flow:
$-23.97M
1W Performance:
-4.94%
1M Performance:
-9.07%
6M Performance:
+83.92%
1Y Performance:
+34.81%
1-Day Range:
$7.16
$7.78
1-Week Range:
$7.16
$7.855
52-Week Range:
$2.54
$9.60
Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile
Name
Corvus Pharmaceuticals Inc
Sector
Industry
Phone
(650) 900-4520
Address
863 MITTEN ROAD, BURLINGAME, CA
Compare CRVS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRVS
Corvus Pharmaceuticals Inc
|
7.32 | 575.05M | 0 | -27.03M | -23.97M | -0.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-13-25 | Initiated | Barclays | Overweight |
| Jan-02-25 | Initiated | H.C. Wainwright | Buy |
| Aug-18-23 | Initiated | Oppenheimer | Outperform |
| Dec-01-21 | Resumed | Jefferies | Buy |
| May-27-21 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-10-21 | Downgrade | Mizuho | Buy → Neutral |
| Sep-12-19 | Initiated | Mizuho | Buy |
| May-29-19 | Initiated | ROTH Capital | Buy |
| Aug-24-17 | Upgrade | Credit Suisse | Underperform → Neutral |
| May-01-17 | Downgrade | Credit Suisse | Neutral → Underperform |
| Apr-18-16 | Initiated | Credit Suisse | Outperform |
| Apr-18-16 | Initiated | Guggenheim | Buy |
View All
Corvus Pharmaceuticals Inc Stock (CRVS) Latest News
Corvus Pharmaceuticals (NASDAQ:CRVS) Stock Price Down 6.5%Should You Sell? - MarketBeat
Is Corvus Pharmaceuticals Inc a good long term investmentInsider Trading Activity & Free Real-Time Trading Signals - earlytimes.in
How strong is Corvus Pharmaceuticals Inc. stock balance sheetRetail Trading Trends & Free Trading Signals to Sharpen Your Edge - bollywoodhelpline.com
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Up 3.5%Here's Why - MarketBeat
Corvus Pharmaceuticals, Inc.(NasdaqGM:CRVS) added to S&P Biotechnology Select Industry Index - marketscreener.com
IPO Launch: Will Corvus Pharmaceuticals Inc. stock split attract more investors2025 Earnings Surprises & Reliable Intraday Trade Plans - moha.gov.vn
How Chegg, Inc. stock performs during market volatility - Улправда
Will Corvus Pharmaceuticals Inc. stock gain from lower inflationWeekly Earnings Recap & Weekly Top Stock Performers List - Улправда
Will Corvus Pharmaceuticals Inc. stock split attract more investorsJuly 2025 Selloffs & Real-Time Stock Movement Alerts - Улправда
Aug Macro: Why Corvus Pharmaceuticals Inc. stock appeals to dividend seekersJuly 2025 Opening Moves & Weekly Stock Breakout Alerts - Улправда
Can Corvus Pharmaceuticals Inc. stock reach $100 price targetWeekly Gains Report & Community Consensus Picks - Улправда
Hedge Fund Moves: How strong is Corvus Pharmaceuticals Inc. stock balance sheet2025 Sector Review & Momentum Based Trading Signals - ulpravda.ru
Street Watch: Will Corvus Pharmaceuticals Inc. stock split attract more investors2025 Sector Review & Daily Stock Trend Watchlist - Улправда
Corvus Pharmaceuticals Earnings Notes - Trefis
Corvus Pharmaceuticals stock awaits key January 2026 trial data By Investing.com - Investing.com Canada
What is Corvus Pharmaceuticals Inc (CRVS) Stock Return on Shareholders’ Capital? - setenews.com
Eczema Clinical Trial Pipeline Accelerates as 100+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - The Manila Times
Corvus Pharmaceuticals (NASDAQ:CRVS) Trading 7.1% HigherWhat's Next? - MarketBeat
Corvus Pharmaceuticals Reports Promising Phase 1 Data for Soquelitinib in Relapsed/Refractory T Cell Lymphoma at ASH Annual Meeting - Quiver Quantitative
Corvus Pharmaceuticals Presents Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial - The Manila Times
Corvus Pharma (CRVS) Stock Analysis Report | Financials & Insights - Benzinga
Corvus Pharmaceuticals (NASDAQ:CRVS) Sets New 12-Month HighHere's What Happened - MarketBeat
You might want to take a look at Corvus Pharmaceuticals Inc (CRVS) now - setenews.com
Will Corvus Pharmaceuticals Inc. stock split again soonMarket Performance Report & Growth Focused Investment Plans - Newser
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Corvus Pharmaceuticals (NASDAQ:CRVS) Stock Price Down 8%Here's What Happened - MarketBeat
Here's Why We're Not Too Worried About Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation - Yahoo Finance
Is Corvus Pharmaceuticals Inc. stock a buy before product launchesDividend Hike & Intraday High Probability Alerts - Newser
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Perhaps timely catching Corvus Pharmaceuticals Inc (CRVS) would be a good idea - Setenews
Foresite Capital Management VI LLC Boosts Position in Corvus Pharmaceuticals, Inc. $CRVS - MarketBeat
Corvus Pharmaceuticals: Trial Momentum Keeps Stock In Focus - RTTNews
What risks investors should watch in Corvus Pharmaceuticals Inc. stockWeekly Trend Summary & Weekly Watchlist for Consistent Profits - newser.com
Will Corvus Pharmaceuticals Inc. stock reach Wall Street targetsPortfolio Growth Summary & Technical Buy Zone Confirmation - newser.com
Is Corvus Pharmaceuticals Inc. stock affected by interest rate hikes2025 Geopolitical Influence & Consistent Profit Trading Strategies - newser.com
Is Corvus Pharmaceuticals Inc. stock supported by innovation pipeline2025 Analyst Calls & Consistent Profit Trading Strategies - newser.com
What valuation multiples suggest for Corvus Pharmaceuticals Inc. stockRecession Risk & AI Forecast Swing Trade Picks - newser.com
Corvus Pharmaceuticals Inc. stock momentum explainedWeekly Profit Report & Verified Swing Trading Watchlist - newser.com
Its Stock Has Paid Off Big Time For Corvus Pharmaceuticals Inc - Setenews
Corvus Pharmaceuticals Inc Stock (CRVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):